Found 706 clinical trials
The OVAL Study: A Randomized Controlled Double-Arm Double-Blind Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined with Paclitaxel vs. Paclitaxel Combined with Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
This double-blind, randomized controlled trial will examine the safety and tolerability of the combination of intravenous administration of VB-111 and paclitaxel compared to placebo and paclitaxel in patients with platinum resistant ovarian cancer.
Serenity for All
You are invited to participate in this online research survey, Serenity for All. We are aiming to get 100 people to complete this survey. In order to participate in this study, you have to be at least 18 years old.
Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole as Adjunctive Therapy in the Maintenance Treatment of Adults With Major Depressive Disorder
You are being asked to take part in this study because you have been diagnosed with major depressive disorder (depression). Brexpiprazole is a medication being studied as a possible treatment for adjunctive treatment for Major Depressive Disorder (MDD). It was first approved in the United States (10 July 2015) for …
Development of a reliable means for functional assessment of liver performance after Fontan operation: dual cholate clearance assay
With vastly improved survival for babies born with congenital heart disease (CHD), there is increasing attention on long-term outcomes in adulthood, especially those born with severe forms of CHD. One area of intense research is liver disease in Fontan patients, the nature of which is incompletely understood. It is known …
A Phase 1/2 Randomized Double-Blind Placebo-Controlled Combined Single and Multiple Ascending Dose Study Evaluating the Safety Tolerability and Biological Activity of MRT5005 (COhCFTR mRNA/ICE LNP) Administered by Nebulization to Adult Subjects with Cystic Fibrosis
This research study is being done to study a new way to possibly treat cystic fibrosis lung disease. The investigational drug to be tested in the present study is known by its code name MRT5005. MRT5005 consists of very small particles containing messenger ribonucleic acid (mRNA), which has the genetic …
Evaluation of the VISITAG SURPOINT Module with External Processing Unit (EPU) when used with the THERMOCOOL SMARTTOUCH SF and the THERMOCOOL SMARTTOUCH Catheters for Pulmonary Vein Isolation (PVI)
This is a single-arm trial design for Biosense Webster's post-marketing study evaluating the effectiveness and safety of VISITAG SURPOINT Module with External Processing Unit (EPU) when used with the THERMOCOOL SMARTTOUCH® SF catheter (STSF)catheter for pulmonary vein isolation (PVI). The trial will enroll total of 330 subjects, to achieve a …
A Phase 2 Study of PTG-300 in Non-Transfusion Dependent (NTD) and Transfusion-Dependent (TD) Beta-Thalassemia Subjects with Chronic Anemia.
This is a Phase 2 open-label, single-arm design with dose escalation by subject cohort and with the potential for individual titration (dose increase or decrease) within each cohort. Five PTG-300 dose levels/regimens are planned to be tested for each subpopulation of beta-thalassemia (NTD and TD) on separate arms: Cohort 1: …
UPCC 15518 / ANAM-17-21: A Phase 3 Randomized Double-Blind Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
The main purpose of this study is to learn more about how well the experimental drug, anamorelin hydrochloride (HCl), works to prevent weight loss and anorexia in patients with advanced Non-Small Cell Lung Cancer.
A phase II single-arm open-label multi-center study of sirolimus in previously treated idiopathic multicentric Castleman disease
The purpose of this study is to determine the effects of sirolimus in patients (males or females aged 18-80) with idiopathic multicentric Castleman Disease (iMCD) who are either unable to tolerate siltuximab or tocilizumab, or have failed, relapsed, or are refractory to this treatment. Subjects will take sirolimus daily for …
Novel neural circuit biomarkers of major depression response to computer-augmented CBT (1R01MH110939 - 01A1)
This is a trial of an FDA-approved treatment for Major Depressive Disorder (MDD), computer-augmented cognitive behavioral therapy (CCBT), to examine novel potential neural circuit biomarkers of treatment response rather than to test efficacy. We will enroll 60 subjects, 18-60 years, who are seeking treatment for a current episode of Major …
